SOUTH SAN FRANCISCO, Calif., May 20, 2024 /PRNewswire/ -- Rila Therapeutics, Inc., A biotechnology company focused on addressing the burden of chronic fibrotic diseases, today announced that the first cohort of subjects was dosed in a phase 1 trial of RLA-23174 in China in collaboration with our development partner, Yingli Pharmaceutical.

加利福尼亚州南旧金山，2024年5月20日/PRNewswire/--专注于解决慢性纤维化疾病负担的生物技术公司Rila Therapeutics，Inc.今天宣布，第一批受试者与我们的开发合作伙伴英利制药（Yingli Pharmaceutical）合作，在中国进行RLA-23174的一期临床试验。

RLA-23174 is a first-in-class small molecule allosteric inhibitor of HIPK2 which inhibits TGF-β signaling to address FSGS and other fibrotic diseases. The phase 1 placebo-controlled study for RLA-23174 is designed to assess its safety at multiple dose levels, tolerability, food effect, and pharmacokinetics.

RLA-23174是HIPK2的一流小分子变构抑制剂，可抑制TGF-β信号传导以解决FSGS和其他纤维化疾病。RLA-23174的1期安慰剂对照研究旨在评估其在多剂量水平，耐受性，食物效应和药代动力学方面的安全性。

The single-center trial is enrolling healthy subjects and consists of staggered single ascending dose and multiple ascending dose cohorts. The trial will enroll up to 80 patients with expected completion by the end of 3Q2024 to support advancement into the Phase 2 clinical program..

单中心试验正在招募健康受试者，由交错的单次递增剂量和多次递增剂量队列组成。该试验将招募多达80名患者，预计在2024年第3季度末完成，以支持进入2期临床计划。。

About RLA-23174RLA-23174 is a new small molecule allosteric inhibitor of HIPK2 and a potential first-in-class treatment for pan-organ fibrosis. RLA-23174 inhibits the TGF-β/Smad3 signaling pathway by affecting the interaction between HIPK2 and Smad3, without inhibiting the kinase activity of HIPK2 or TGF-β receptor systems.

关于RLA-23174RLA-23174是HIPK2的新型小分子变构抑制剂，是泛器官纤维化的潜在一流治疗方法。RLA-23174通过影响HIPK2和Smad3之间的相互作用来抑制TGF-β/Smad3信号通路，而不抑制HIPK2或TGF-β受体系统的激酶活性。

Therefore, RLA-23174 exerts anti-fibrotic effects by reducing TGF-β signaling without serious adverse effects caused by complete HIPK2 or TGF-β signaling blockade. Preclinical studies have shown that RLA-23174 has superior anti-fibrotic effects, significant in vivo activity, excellent pharmacokinetic properties in animals, and a good safety profile.

因此，RLA-23174通过减少TGF-β信号传导而发挥抗纤维化作用，而没有由完全HIPK2或TGF-β信号传导阻断引起的严重不良反应。临床前研究表明，RLA-23174具有优异的抗纤维化作用，显着的体内活性，优异的动物药代动力学特性以及良好的安全性。

RLA-23174 demonstrates good druggability and excellent development potential..

RLA-23174具有良好的可药用性和良好的发展潜力。。

'Dosing of the first cohort in this first human study with RLA-23174 is a meaningful milestone for Rila Therapeutics. It signifies our evolution into a clinical development company bringing us closer to helping patients with kidney disease,' stated Robert Drakas, Ph.D., Chief Executive Officer of Rila Therapeutics..

“在这项首次人类研究中，用RLA-23174给药的第一个队列是Rila治疗学的一个有意义的里程碑。Rila Therapeutics首席执行官罗伯特·德拉卡斯（RobertDrakas）博士表示，这标志着我们发展成为一家临床开发公司，使我们更接近于帮助肾脏疾病患者。。

'Regardless of several newly approved therapies for chronic kidney disease (CKD), many patients still progress to kidney failure, requiring dialysis or transplantation. Therefore, there is an urgent need to develop more effective drugs to halt disease progression, and we strongly believe that anti-fibrosis drug is one of the most promising drugs for such therapy.

“尽管有几种新批准的慢性肾病（CKD）治疗方法，但许多患者仍会发展为肾衰竭，需要透析或移植。因此，迫切需要开发更有效的药物来阻止疾病进展，我们坚信抗纤维化药物是这种治疗最有希望的药物之一。

We are hopeful that HIPK2 inhibitor molecules/RLA-23174 could provide additional renal protection in conjunction with the current therapies for CKD. The Initiation of the phase 1 clinical trial of RLA-23174 is an important milestone for Rila. RLA-23174 exemplifies Rila's commitment to discovering and developing novel precision medicines for severe chronic kidney diseases,' said founder John He, MD, PhD, Chief of Nephrology at Icahn Mount Sinai and key opinion leader at one of the largest medical centers in the US. .

我们希望HIPK2抑制剂分子/RLA-23174可以结合目前的CKD治疗提供额外的肾脏保护。RLA-23174的1期临床试验的启动是Rila的重要里程碑。“RLA-23174体现了Rila致力于发现和开发治疗严重慢性肾脏疾病的新型精准药物的承诺，”伊坎西奈山肾脏病学负责人、美国最大医疗中心之一的关键意见领袖约翰·何博士说。

About Rila TherapeuticsRila Therapeutics is focused on developing first-in-class medicines to treat fibrotic diseases. Rila was founded on exploring novel areas of biology focused on stopping fibrosis progression. Rila's programs target key molecular pathways whose dysfunction are hallmarks of renal fibrosis.

关于Rila Therapeutics IRA Therapeutics专注于开发一流的治疗纤维化疾病的药物。Rila成立于探索新的生物学领域，专注于阻止纤维化进展。Rila的计划针对的是关键的分子途径，其功能障碍是肾纤维化的标志。

Rila is building its pipeline by leveraging insights into the dynamic process of fibrosis progression to discover and develop therapeutics with differentiating mechanisms of action against fibrotic pathways.For more information, please visit www.rilatx.com.

Rila正在通过深入了解纤维化进展的动态过程来发现和开发具有针对纤维化途径的不同作用机制的治疗方法，从而建立其管道。有关更多信息，请访问www.rilatx.com。